• Developing a new class of synthetic anti-infectives to address antibiotic resistance
• Phase 3 clinical trial for diabetic foot infections underway in Indonesia
• Successful Phase 1/2 trials for topical gel formulations across various indications

Recce Pharmaceuticals Ltd, a publicly-traded Australian clinical-stage biotech company, presented an investor webinar detailing its progress in developing a new class of synthetic anti-infectives to address the global healthcare crisis of antibiotic resistance. The company's lead candidate, RECCE 327, has been granted Qualified Infectious Disease Product (QIDP) designation by the U.S. FDA, providing 10 years of market exclusivity and fast-track approval. RECCE 327 has also been added to the World Health Organization's List of Antibacterial Products in Clinical Development. The webinar highlighted Recce's strong management team, led by CEO James Graham, and its diverse pipeline of topical, intravenous, and inhaled formulations targeting a broad spectrum of infections, including serious and life-threatening indications. The company has successfully completed multiple Phase 1 and Phase 2 clinical trials across Australia, demonstrating the safety and efficacy of its topical gel formulation in treating conditions such as diabetic foot infections (DFIs), acute bacterial skin and skin structure infections (ABSSSI), and burn wound infections.Recce is currently conducting a Phase 3, double-blind, placebo-controlled study of its RECCE 327 topical gel for the treatment of DFIs in Indonesia, with over 20 million adults living with diabetes in the country. The trial is being conducted across multiple sites, and an interim data analysis is planned after 155 patients. The company's goal is to have RECCE 327 registered in Indonesia and the ASEAN region by 2026-2027.The webinar also covered Recce's strategic partnership with PT Etana Biotechnologies, a leading Indonesian biomedical organization, to accelerate the clinical development and commercialization of RECCE 327 in the region. The partnership aims to facilitate late-stage trials and support the Indonesian government's efforts to address infectious diseases and antimicrobial resistance.Additionally, the webinar highlighted Recce's engagement with the U.S. Department of Defense, including grants from the U.S. Defense Burn Research Program and the U.S. Army Medical Research Institute of Infectious Diseases, which are exploring the potential of RECCE 327 for warfighter health countermeasures and biodefense applications.

Recce Pharmaceuticals is focused on advancing its RECCE 327 candidate through late-stage clinical trials and regulatory approvals, with the goal of making the product available in Indonesia and the ASEAN region by 2026-2027. The company is also exploring partnerships and funding opportunities to support the continued development and commercialization of its novel anti-infective technologies.